Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has dosed the first patient in its Phase 2 clinical trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of the signs and symptoms of dry eye disease.
Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter and year end financial results on Thursday, March 11, 2021. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to review the Co...
Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences:
Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. Mistakes are...
If so, there are a few names in the healthcare sector that deserve your attention. Investors can expect big gains ahead from shares of Clover Health (NASDAQ: CLOV), Fulgent Genetics (NASDAQ: FLGT), and Ocular Therapeutix (NASDAQ: OCUL). It's still early, but it looks like a promising new insurer called Clover Health could be the first to actually lower costs and deliver profits to investors.
Shares of Ocular Therapeutix (NASDAQ: OCUL) have more than tripled investors' money over the past year as the company's long-lasting eye treatments took big steps forward. Despite the big gains it's already produced, this soaring biotech stock hasn't reached a peak yet. Like most smart investment decisions, there's more than one good reason to buy Ocular Therapeutix at the moment.
Ocular Therapeutix Inc (NASDAQ: OCUL) on Friday released limited data from its presentation on the ongoing Phase 1 trial evaluating OTX-TKI for wet age-related macular degeneration and other retinal diseases. Ocular presented the data at the Angiogenesis, Exudations, and Degeneration 2021 Meeting. OTX-TKI is an axitinib intravitreal implant for the treatment of wet age-related macular degeneration (AMD). Interim data showed that some subjects showed a decrease in the intraretinal or subretinal f...
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced its intention to present data from its Phase 1 clinical trial of OTX-TKI, an axitinib intravitreal implant for the treatment of patients with wet age-related macular degeneration (wet AMD) and other retinal diseases, at the upcoming Angiogenesis, Exudations, and Degeneration 2021 Meeting bein...
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has granted (i) a non-statutory stock option to purchase up to an aggregate of 100,000 shares of common stock of Ocular Therapeutix subject to time-based vesting (the "Time-Based Option") and (ii) a non-statutory stock option to purchase up to an aggregate of 50,000 shares of comm...